Charles River Laboratories Shares Outstanding 2006-2018 | CRL

Charles River Laboratories shares outstanding history from 2006 to 2018. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
  • Charles River Laboratories shares outstanding for the quarter ending September 30, 2018 were 0.049B, a 1.93% increase year-over-year.
  • Charles River Laboratories 2017 shares outstanding were 0.049B, a 1.26% increase from 2016.
  • Charles River Laboratories 2016 shares outstanding were 0.048B, a 0.68% increase from 2015.
  • Charles River Laboratories 2015 shares outstanding were 0.048B, a 0.16% increase from 2014.
Charles River Laboratories Annual Shares Outstanding
(Millions of Shares)
2017 49
2016 48
2015 48
2014 48
2013 48
2012 48
2011 51
2010 63
2009 66
2008 67
2007 69
2006 70
2005 73
Charles River Laboratories Quarterly Shares Outstanding
(Millions of Shares)
Q3 2018 49
Q2 2018 49
Q1 2018 49
Q4 2017 49
Q3 2017 48
Q2 2017 48
Q1 2017 48
Q4 2016 48
Q3 2016 48
Q2 2016 48
Q1 2016 48
Q4 2015 48
Q3 2015 47
Q2 2015 48
Q1 2015 48
Q4 2014 48
Q3 2014 47
Q2 2014 48
Q1 2014 48
Q4 2013 48
Q3 2013 48
Q2 2013 49
Q1 2013 48
Q4 2012 48
Q3 2012 48
Q2 2012 48
Q1 2012 49
Q4 2011 51
Q3 2011 51
Q2 2011 52
Q1 2011 55
Q4 2010 63
Q3 2010 63
Q2 2010 66
Q1 2010 66
Q4 2009 66
Q3 2009 65
Q2 2009 65
Q1 2009 66
Q4 2008 67
Q3 2008 71
Q2 2008 70
Q1 2008 71
Q4 2007 69
Q3 2007 69
Q2 2007 69
Q1 2007 68
Q4 2006 70
Q3 2006 68
Q2 2006 72
Q1 2006 73
Q4 2005 73
Q3 2005 73
Q2 2005 73
Q1 2005 73
Sector Industry Market Cap Revenue
Medical Medical Services $6.310B $1.858B
Charles River Laboratories International, Inc. provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Their dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. At Charles River, they are passionate about their role in improving the quality of people's lives. Their mission, their excellent science and strong sense of purpose guide in all that they do, and they approach each day with the knowledge that their work helps to improve the health and well-being of many across the globe. Charles River Laboratories International, Inc. service areas are Basic research, discovery, safety and efficacy, clinical support and manufacturing.
Stock Name Country Market Cap PE Ratio
Express Scripts Holding (ESRX) United States $54.627B 11.29
ICON (ICLR) Ireland $7.463B 23.39
PRA Health Sciences (PRAH) United States $6.620B 27.02
HealthEquity (HQY) United States $5.521B 115.57
Premier (PINC) United States $5.378B 18.33
INC Research Holdings (SYNH) United States $5.128B 20.70
Teladoc (TDOC) United States $4.102B 0.00
NovoCure (NVCR) Jersey $2.920B 0.00
AMN Healthcare Services Inc (AMN) United States $2.679B 18.38
Medpace Holdings (MEDP) United States $2.042B 25.26
BioTelemetry (BEAT) United States $2.004B 35.41
Healthways (TVTY) United States $1.482B 18.23
Intrexon (XON) United States $1.385B 0.00
IKang Healthcare (KANG) China $1.075B 53.38
CareDx (CDNA) United States $0.992B 0.00
Natera (NTRA) United States $0.986B 0.00
China Cord Blood (CO) China $0.800B 21.23
Surgery Partners (SGRY) United States $0.669B 0.00
Apollo Medical Holdings (AMEH) United States $0.600B 0.00
Establishment Labs Holdings (ESTA) $0.553B 0.00
Civitas Solutions (CIVI) United States $0.526B 10.37
OncoCyte (OCX) United States $0.074B 0.00
Interpace Diagnostics (IDXG) United States $0.042B 0.00
Cancer Genetics (CGIX) United States $0.017B 0.00
OpGen (OPGN) United States $0.008B 0.00
FORM Holdings (XSPA) United States $0.005B 0.00
Biocept (BIOC) United States $0.004B 0.00